flucytosine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1188 | 2022-85-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A fluorinated cytosine analog that is used as an antifungal agent.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | g | O |
| 10 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 15 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 99 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 1161.94 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 84 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.68 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.20 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 26, 1971 | FDA | VALEANT |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Immune reconstitution inflammatory syndrome | 114.11 | 58.49 | 23 | 578 | 5651 | 56285815 |
| Cryptococcosis | 64.93 | 58.49 | 11 | 590 | 1035 | 56290431 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Disseminated cryptococcosis | 173.62 | 47.33 | 32 | 1194 | 1328 | 31694790 |
| Immune reconstitution inflammatory syndrome | 149.70 | 47.33 | 39 | 1187 | 8139 | 31687979 |
| Meningitis cryptococcal | 138.96 | 47.33 | 29 | 1197 | 2294 | 31693824 |
| Cryptococcosis | 133.00 | 47.33 | 28 | 1198 | 2310 | 31693808 |
| Drug ineffective | 115.95 | 47.33 | 105 | 1121 | 395468 | 31300650 |
| Cerebral cyst | 58.77 | 47.33 | 10 | 1216 | 258 | 31695860 |
| Intracranial pressure increased | 55.36 | 47.33 | 15 | 1211 | 3600 | 31692518 |
| Muscle abscess | 52.09 | 47.33 | 10 | 1216 | 513 | 31695605 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Immune reconstitution inflammatory syndrome | 255.23 | 41.35 | 61 | 1847 | 12929 | 70913607 |
| Disseminated cryptococcosis | 209.31 | 41.35 | 37 | 1871 | 1750 | 70924786 |
| Cryptococcosis | 192.61 | 41.35 | 38 | 1870 | 3272 | 70923264 |
| Meningitis cryptococcal | 174.31 | 41.35 | 35 | 1873 | 3293 | 70923243 |
| Drug ineffective | 165.45 | 41.35 | 160 | 1748 | 939592 | 69986944 |
| Cerebral cyst | 59.55 | 41.35 | 10 | 1898 | 346 | 70926190 |
| Intracranial pressure increased | 58.98 | 41.35 | 17 | 1891 | 7339 | 70919197 |
| Muscle abscess | 49.58 | 41.35 | 10 | 1898 | 956 | 70925580 |
| Liver transplant failure | 46.39 | 41.35 | 7 | 1901 | 120 | 70926416 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AE21 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use |
| ATC | J02AX01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Other antimycotics for systemic use |
| FDA EXT | N0000175459 | Nucleoside Analog |
| FDA EPC | N0000175467 | Nucleoside Analog Antifungal |
| CHEBI has role | CHEBI:50266 | Prodrugs |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D009676 | Noxae |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Systemic Cryptococcosis Treatment Adjunct | indication | ||
| Synergy for Candida Infection | indication | ||
| Systemic Candidiasis Treatment Adjunct | indication | ||
| Candidal Urinary Tract Infection | indication | ||
| Synergy for Cryptococcal Infection | indication | ||
| Chromoblastomycosis | off-label use | 187079000 | |
| Hypokalemia | contraindication | 43339004 | |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Radiation oncology AND/OR radiotherapy | contraindication | 108290001 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Aplastic anemia due to drugs | contraindication | 267527002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Bone marrow depression | contraindication | 307762000 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Granulocytopenic disorder | contraindication | 417672002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.56 | acidic |
| pKa2 | 2.7 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | GPCR | IC50 | 5.10 | WOMBAT-PK | |||||
| Thymidylate synthase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Thymidylate synthase | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
| ATP-dependent molecular chaperone HSP82 | Cytosolic other | EC50 | 6.15 | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4017792 | VUID |
| N0000146153 | NUI |
| D00323 | KEGG_DRUG |
| 4017792 | VANDF |
| C0016278 | UMLSCUI |
| CHEBI:5100 | CHEBI |
| 1LD | PDB_CHEM_ID |
| CHEMBL1463 | ChEMBL_ID |
| 3366 | PUBCHEM_CID |
| DB01099 | DRUGBANK_ID |
| D005437 | MESH_DESCRIPTOR_UI |
| 2729 | INN_ID |
| D83282DT06 | UNII |
| 227633 | RXNORM |
| 186215 | MMSL |
| 4733 | MMSL |
| 525 | MMSL |
| d00038 | MMSL |
| 002898 | NDDF |
| 28506006 | SNOMEDCT_US |
| 387155003 | SNOMEDCT_US |
| CHEMBL170073 | ChEMBL_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0427 | CAPSULE | 250 mg | ORAL | ANDA | 22 sections |
| flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0428 | CAPSULE | 500 mg | ORAL | ANDA | 22 sections |
| ANCOBON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-3554 | CAPSULE | 250 mg | ORAL | NDA | 23 sections |
| ANCOBON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-3554 | CAPSULE | 250 mg | ORAL | NDA | 23 sections |
| ANCOBON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-3555 | CAPSULE | 500 mg | ORAL | NDA | 23 sections |
| ANCOBON | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-3555 | CAPSULE | 500 mg | ORAL | NDA | 23 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6834 | CAPSULE | 250 mg | ORAL | ANDA | 20 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6834 | CAPSULE | 250 mg | ORAL | ANDA | 20 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6835 | CAPSULE | 500 mg | ORAL | ANDA | 20 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6835 | CAPSULE | 500 mg | ORAL | ANDA | 20 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40032-770 | CAPSULE | 500 mg | ORAL | ANDA | 18 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40032-771 | CAPSULE | 250 mg | ORAL | ANDA | 18 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42494-339 | CAPSULE | 250 mg | ORAL | NDA authorized generic | 26 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42494-339 | CAPSULE | 250 mg | ORAL | NDA authorized generic | 26 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42494-340 | CAPSULE | 500 mg | ORAL | NDA authorized generic | 26 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42494-340 | CAPSULE | 500 mg | ORAL | NDA authorized generic | 26 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-009 | CAPSULE | 250 mg | ORAL | ANDA | 14 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-010 | CAPSULE | 500 mg | ORAL | ANDA | 14 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-770 | CAPSULE | 500 mg | ORAL | ANDA | 18 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-771 | CAPSULE | 250 mg | ORAL | ANDA | 18 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-331 | CAPSULE | 250 mg | ORAL | ANDA | 18 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-331 | CAPSULE | 250 mg | ORAL | ANDA | 18 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-332 | CAPSULE | 500 mg | ORAL | ANDA | 18 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-332 | CAPSULE | 500 mg | ORAL | ANDA | 18 sections |
| FLUCYTOSINE | Human Prescription Drug Label | 1 | 59651-331 | CAPSULE | 250 mg | ORAL | ANDA | 21 sections |
| FLUCYTOSINE | Human Prescription Drug Label | 1 | 59651-331 | CAPSULE | 250 mg | ORAL | ANDA | 21 sections |
| FLUCYTOSINE | Human Prescription Drug Label | 1 | 59651-332 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
| FLUCYTOSINE | Human Prescription Drug Label | 1 | 59651-332 | CAPSULE | 500 mg | ORAL | ANDA | 21 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-352 | CAPSULE | 250 mg | ORAL | ANDA | 19 sections |
| Flucytosine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-363 | CAPSULE | 500 mg | ORAL | ANDA | 19 sections |